India’s Zydus Cadila Buys Etna Of Holland To Expand Vaccine Research
This article was originally published in PharmAsia News
Executive Summary
India's Zydus Cadila says it has acquired Etna Biotech, a subsidiary of Crucell of the Netherlands. The acquisition is the sixth by Cadila in the past five years and is aimed at giving the Indian drug maker entry into vaccine innovation. Details of the purchase were not revealed. Cadila cited Etna's expertise in research and development and its "highly evolved research platform" for developing vaccines. (Click here for more